NEW YORK (GenomeWeb News) – Personalized medicine software company MediSapiens has raised $1 million in seed funding from Veraventure, ETF III, VTT Ventures, and Lifeline Ventures.
The Helsinki-based company provides a software database platform that provides genomic data about cancer and cancer treatments that can be used to develop personalized therapies.
The software is based on technology developed at the VTT Technical Research Centre of Finland, and it serves as host to the VTT's gene expression database, which provides data that oncologists can use to evaluate individual genetic signatures for optimizing treatment.
"The latest research — such as The Cancer Genome Atlas funded by the NIH — demonstrates that every patient's cancer is a complex, unique combination of genetic mutations and abnormally expressed genes," MediSapiens CEO and Co-founder Tommi Pisto said in a statement.
"Making use of the data produced by the global scientific community provides a new and significant opportunity to understand cancer," added Olli Kallioniemi, a MediSapiens board member and director of the Institute for Molecular Medicine in Finland. "Oncologists can benefit when these reference datasets are used to interpret molecular profiling results for individual patients."